You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Modified Folfirinox

Showing 1 - 25 of 4,742
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Pancreatic Adenocarcinoma Trial in Ann Arbor (Devimistat, Modified FOLFIRINOX)

Not yet recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • Ann Arbor, Michigan
    Rogel Cancer Center
Jun 26, 2023

Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)

Recruiting
  • Mucinous Ovarian Cancer
  • +2 more
  • Bevacizumab + modified FOLFIRINOX
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 25, 2022

C04.588.274.476.411.307 Trial (CPI-613, modified FFX, Bevacizumab)

Not yet recruiting
  • C04.588.274.476.411.307
  • (no location specified)
Nov 10, 2022

Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma Trial in Washington (Eryaspase,

Active, not recruiting
  • Locally Advanced Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Aug 3, 2022

Pancreatic Cancer Trial in Cleveland (CPI 613, Oxaliplatin, Irinotecan)

Active, not recruiting
  • Pancreatic Cancer
  • CPI 613
  • +4 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Sep 14, 2022

Pancreatic Ductal Adenocarcinoma Trial (JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • (no location specified)
Feb 16, 2022

Resectable Pancreatic Adenocarcinoma Trial in Seoul (neoadjuvant modified FOLFIRINOX)

Recruiting
  • Resectable Pancreatic Adenocarcinoma
  • neoadjuvant modified FOLFIRINOX
  • Seoul, Korea, Republic of
    Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ.
Sep 23, 2021

Pancreatic Ductal Adenocarcinoma Trial in New York (Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Stereotactic body radiotherapy (SBRT)
  • +4 more
  • New York, New York
    Columbia University Irving Medical Center
Sep 15, 2023

Metastatic Pancreatic Cancer Trial in Long Branch, New Brunswick (Folfirinox alternating with Gemcitabine-nab-Paclitaxel)

Recruiting
  • Metastatic Pancreatic Cancer
  • Folfirinox alternating with Gemcitabine-nab-Paclitaxel
  • Long Branch, New Jersey
  • +1 more
Jun 8, 2021

Metastatic Pancreatic Ductal Adenocarcinoma Trial in France, Spain (CAN04, FOLFIRINOX)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Bordeaux, France
  • +7 more
May 16, 2022

Pancreatic Cancer Trial in Worldwide (ABBV-927, Budiglimab, modified FOLFIRINOX)

Recruiting
  • Pancreatic Cancer
  • Springdale, Arkansas
  • +23 more
May 23, 2022

Pancreatic Cancer Trial in United States (MVT-5873, modified FOLFIRINOX (mFOLFIRINOX))

Recruiting
  • Pancreatic Cancer
  • Scottsdale, Arizona
  • +3 more
Aug 17, 2022

Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma Trial in Shanghai (Nab paclitaxel plus

Recruiting
  • Borderline Resectable Pancreatic Cancer
  • Locally Advanced Pancreatic Adenocarcinoma
  • Shanghai, Shanghai, China
    Department of Pancreatic Surgery, Fudan University Shanghai Canc
Jan 27, 2022

Bile Duct Cancer Trial in France (GEMCIS, mFolfirinox)

Completed
  • Bile Duct Cancer
  • Amiens, France
  • +41 more
Feb 23, 2022

Urachal Cancer Trial in Seoul (FOLFIRINOX)

Recruiting
  • Urachal Cancer
  • Seoul, Korea, Republic of
    Asan Medical Center
Oct 29, 2020

Biliary Tract Cancer Trial in Busan (5-Fluorouracil, Leucovorin, Irinotecan)

Completed
  • Biliary Tract Cancer
  • Busan, Korea, Republic of
    Dong-A University Hospital
Feb 2, 2021

Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic

Unknown status
  • Cholangiocarcinoma of the Bile Duct
    • Shanghai, Shanghai, China
      Xinhua Hospital
    Dec 30, 2020

    Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer Trial in United

    Active, not recruiting
    • Acinar Cell Adenocarcinoma of the Pancreas
    • +4 more
    • Fairfield, Connecticut
    • +8 more
    Oct 31, 2022

    Pancreatic Adenocarcinoma Trial (Nab paclitaxel, Gemcitabine, mFOLFIRINOX)

    Not yet recruiting
    • Pancreatic Adenocarcinoma
    • Nab paclitaxel
    • +2 more
    • (no location specified)
    Apr 6, 2021

    Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer Trial in

    Active, not recruiting
    • Acinar Cell Adenocarcinoma of the Pancreas
    • +3 more
    • 6,8-bis(benzylthio)octanoic acid
    • +5 more
    • Winston-Salem, North Carolina
      Comprehensive Cancer Center of Wake Forest University
    Dec 22, 2021

    Neuroendocrine Carcinoma Trial in France (FOLFOXIRI Protocol, Cisplatin injection)

    Recruiting
    • Neuroendocrine Carcinoma
    • FOLFOXIRI Protocol
    • Cisplatin injection
    • Caen, France
    • +5 more
    Apr 13, 2021

    Pancreatic Carcinoma Trial in France (drug, radiation, procedure)

    Recruiting
    • Pancreatic Carcinoma
    • Bordeaux, France
    • +27 more
    Mar 29, 2022

    Pancreatic Cancer Trial in Houston (Oxaliplatin, Irinotecan, 5-FU)

    Completed
    Has Results
    • Pancreatic Cancer
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Jul 24, 2020

    Locally Advanced Malignant Tumor, Rectal Carcinoma Trial in France (drug, other, radiation, procedure)

    Recruiting
    • Locally Advanced Malignant Neoplasm
    • Rectal Carcinoma
    • Induction chemotherapy - modified FOLFIRINOX regimen
    • +3 more
    • Besançon, Doubs, France
    • +18 more
    Jan 2, 2022

    Pancreatic Adenocarcinoma Trial in Seoul (Preoperative modified FOLFIRINOX and postoperative gemcitabine)

    Completed
    • Pancreatic Adenocarcinoma
    • Preoperative modified FOLFIRINOX and postoperative gemcitabine
    • Seoul, Korea, Republic of
      Asan Medical Center, University of Ulsan College of Medicine
    Nov 22, 2019